Untitled

YELLOW FEVER STUDY NOTES

INTRODUCTION

  • Definition: Yellow fever is an acute viral hemorrhagic disease transmitted by female Aedes mosquitoes. It is characterized by liver dysfunction that leads to jaundice, hence the name yellow fever.
  • Virus classification: The virus is classified as an arbovirus within the Family Flaviviridae and the genus Flavivirus.
  • Virus characteristics:
    • It is an enveloped virus.
    • It is a single-stranded RNA virus.
  • Genotypes: Seven genotypes of yellow fever virus have been identified:
    • South America: 2 genotypes (Genotype 1 and 2).
    • Africa: Five genotypes:
    • West Africa genotype 1 (found in Cameroon, Nigeria, and Gabon).
    • West Africa genotype 2 (found in Senegal, Guinea, Ivory Coast, and Ghana).
    • East and Central African genotype (found in Sudan, Ethiopia, Central African Republic, and Democratic Republic of Congo).
    • East African genotype (found in Kenya).
    • Angola genotype (found in Angola).

EPIDEMIOLOGY

  • Endemic regions: Tropical Africa is generally regarded as the yellow fever endemic zone; however, some regions, such as Tanzania, do not experience yellow fever outbreaks.
  • Rapid spread: The disease can spread rapidly and has a fatality rate that may reach as high as 30%.
  • Nature of disease: Yellow fever is classified as a zoonotic and acute hemorrhagic disease.

MODE OF TRANSMISSION

  • Bites: Transmission occurs primarily through the bite of an infected Aedes aegypti mosquito.
  • Human contact: Possible transmission through contact with infected human blood, specifically from day 3 of illness or 2 days prior to fever and 3 to 4 days after the onset of symptoms.
  • Monkey contact: Handling or contact with infected monkeys during early stages of viremia can also lead to transmission.

TRANSMISSION CYCLE

  • Yellow fever has three transmission cycles:
    • Jungle cycle (sylvatic cycle):
    • Involves virus transmission between non-human primates (e.g., monkeys) and mosquito species found in forest canopies.
    • Humans can contract the virus when visiting jungle areas where infected mosquitoes and monkeys coexist.
    • Savannah cycle (intermittent cycle):
    • Transmission occurs from mosquitoes to humans living or working in jungle bordering areas.
    • In this cycle, the virus can be transmitted from monkeys to humans or from humans to humans via mosquito bites.
    • Urban cycle:
    • Involves transmission of the virus between humans and urban mosquitoes, primarily Aedes aegypti.
    • The virus is typically brought into urban settings by a human who was infected in the jungle or savannah.

RISK FACTORS

  • Demographics:
    • Travelers to endemic regions.
    • Individuals with compromised immunity.
    • Pregnant women.
    • Rural or jungle travelers.
  • Occupational exposures:
    • People working in forested areas.
    • History of previous yellow fever infection.
  • Environmental factors:
    • Inadequate mosquito protection (e.g., lack of repellents).
    • Warm and humid environments.
    • Age-related risks (increased susceptibility in the elderly).

PATHOPHYSIOLOGY OF YELLOW FEVER

  • Entry of the virus: The virus enters the body through the bite of an infected mosquito.
  • Replication: After entry, it replicates locally and is transported throughout the body via the lymphatic system.
  • Systemic infection: The virus spreads to major organ systems including:
    • Heart
    • Kidney
    • Liver
    • Lungs
    • Spleen
    • Brain
    • Digestive tract
  • Liver infection:
    • The virus infects hepatic cells, causing cell death and inflammation, which impairs the liver’s ability to process and excrete bilirubin.
    • Dysregulation leads to bilirubin accumulation in blood, resulting in jaundice.
  • Kidney damage: Necrosis occurs in renal tubular epithelium, leading to signs of kidney failure.
  • Gastrointestinal tract (GIT): Damage to blood vessels in the GIT can lead to hemorrhage.
  • Mortality: Death can result from failure of the liver or kidneys, or both, or from failure of the sinoatrial node.

CLINICAL MANIFESTATIONS

  • Phases: Clinical manifestations are divided into two primary phases:
    1. Acute phase:
    • Symptoms include:
      • Fever
      • Muscle pain
      • Backache
      • Headache
      • Shivers
      • Anorexia
      • Nausea and vomiting (notably coffee-colored vomit)
      • Photophobia
      • Dizziness and red eyes.
    1. Toxic phase (occurs in approximately 15% of patients within 24 hours after initial remission):
    • Severity of symptoms increases and may include:
      • Jaundice
      • Bleeding from the eyes, nose, mouth, and stomach (e.g., melena and hematemesis)
      • Abdominal pain
      • Vomiting (notably black vomits)
      • Heart dysfunction
      • Deterioration of kidney function
      • Brain dysfunction (e.g., delirium, seizures, coma)
    • Mortality: Approximately half of the patients may die within 10 to 14 days, while the rest recover without significant organ damage.

DIFFERENTIAL DIAGNOSIS

  • Conditions to consider include:
    • Severe malaria
    • Ebola virus
    • Marburg virus
    • Viral hepatitis
    • Typhoid fever
    • Dengue fever
    • Fungal meningitis
    • Tuberculosis meningitis.

INVESTIGATIONS

To confirm a diagnosis of yellow fever, the following investigations may be conducted:

  • Liver function tests
  • Viral culture (e.g., editor test)
  • Widal test: Blood tests to detect antibodies produced in response to yellow fever.
  • Serological testing: Initially performed using IgM and IgG tests.
  • Polymerase chain reaction (PCR)
  • Renal function tests

MANAGEMENT

  • Patient care: Admit the patient to an isolation unit under a mosquito net.
  • Treatment: No specific antiviral treatment; supportive care is emphasized:
    • Hydration: Administer intravenous fluids (e.g., Ringer's Lactate, normal saline) to prevent dehydration.
    • Monitoring: Monitor vital signs such as temperature, blood pressure, respiratory rate, and pulse rate. Keep track of fluid intake and output on a fluid balance chart.
    • Antipyretics: Administer antipyretics for fever (e.g., ibuprofen or paracetamol) with caution.
    • Pain management: Manage headaches and myalgia with strong opioids (e.g., oral morphine).
    • Respiratory support: Provide supplemental oxygen as needed for respiratory failure or distress.
    • Shock management: Administer vasopressors (e.g., dopamine) for managing shock.
    • Renal support: Hemodialysis or continuous renal replacement therapy may be required.
    • Blood transfusion: In severe hemorrhagic cases, administer fresh frozen plasma.
    • Gastric protection: Administer proton pump inhibitors or H2 blockers to protect the gastric mucosa.
    • Coagulation management: Heparin therapy may be administered for patients with disseminated intravascular coagulation.
    • Antiviral therapy: Consider interferon and antiviral drugs (e.g., ribavirin), noting that it is not effective after the onset of symptoms.

NURSING MANAGEMENT

Key nursing interventions include:

  • Oral care: To prevent halitosis.
  • Medication administration: Ensure proper administration of prescribed medications.
  • Dietary modifications: Encourage a diet rich in protein and low in spicy foods and caffeine.
  • Patient reassurance: Provide reassurance to both the patient and caregivers.
  • Environmental considerations: Keep the patient in a dim and quiet environment to prevent photophobia.
  • Invasive procedure caution: Avoid invasive procedures.
  • Protective measures: Advise wearing long-sleeved clothing and sleeping under treated mosquito nets.

COMPLICATIONS

Potential complications include:

  • Anemia
  • Shock
  • Secondary bacterial infections
  • Hepatic failure
  • Respiratory failure
  • Disseminated intravascular coagulation (DIC)
  • Heart failure
  • Encephalitis
  • Gastrointestinal bleeding
  • Hemorrhagic fever.

PREVENTION

Effective preventative strategies include:

  • Vaccination: Use of the yellow fever 17D vaccine.
  • Travel advisories: Avoid travel to endemic areas.
  • Mosquito protection: Use mosquito repellents and sleep under mosquito nets.
  • Mosquito control: Implement measures to control mosquito populations, such as using pesticides and draining stagnant waters.
  • Avoid high-risk areas: Do not visit forests or other high-risk locations unless necessary.
  • Health education: Provide health education and ensure isolation of infected individuals.

REFERENCES

  • Communicable disease by Dr. Timothy Kingondu
  • Slideshare.net.